Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction

Journal of International Medical Research

Volumn 37, Issue 3, 2009, Pages 601-610

  Liu, B ^a   Yu, G ^a   Yang, Z ^a   Sun, L ^a   Song, R ^a   Liu, F ^a   Xin, Y ^a   Zhang, Liming ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherogenesis; OX40; OX40 ligand; Simvastatin

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BETA ACTIN; CD134 ANTIGEN; GAMMA INTERFERON; GELATINASE B; MESSENGER RNA; MEVALONIC ACID; OX40 LIGAND; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TNFRSF4 PROTEIN, HUMAN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ATHEROSCLEROSIS; BLOOD; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL;

ATHEROSCLEROSIS; CEREBRAL INFARCTION; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OX40 LIGAND; RECEPTORS, OX40; RNA, MESSENGER; SIMVASTATIN;

EID: 70349255757     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700302     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 participants with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. Park KW, Hwang KK, Cho HJ, et al: Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces proangiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta 2008; 388: 156-166.
3. Han SH, Koh KK, Quon MJ, et al: The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 2007; 190: 205-211.
4. Giurgea AG, Margeta C, Maca T, et al: Simvastatin reduces serum level of vascular endothelial growth factor in hypercholesterolemic patients. J Cardiovasc Pharmacol 2006; 47: 30-36. (Pubitemid 44378221)
5. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
6. Neri Serneri GG, Prisco D, Martini F, et al: Acute T-cell activation is detectable in unstable angina. Circulation 1997; 95: 1806-1812. (Pubitemid 27164397)
7. Mazzone A, De Servi S, Ricevuti G, et al: Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-363. (Pubitemid 23228033)
8. Wang X, Ria M, Kelmenson PM, et al: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37: 365-372. (Pubitemid 40490486)
9. Mälarstig A, Eriksson P, Rose L, et al: Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin Chem 2008; 54: 833-840. (Pubitemid 351671600)
10. Liu DM, Yan JC, Wang CP, et al: The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta 2008; 397: 22-26.
11. Paterson DJ, Jefferies WA, Green JR, et al: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987; 24: 1281-1290.
12. Ohshima Y, Tanaka Y, Tozawa H, et al: Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997; 59: 3838-3848. (Pubitemid 127469639)
13. Stüber E, Strober W: The T cell-B cell interaction via OX40-OX40L is necessary for the T celldependent humoral immune response. J Exp Med 1996; 183: 979-989. (Pubitemid 26114798)
14. Sugamura K, Ishii N, Weinberg AD: Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol 2004; 4: 420-431. (Pubitemid 38745554)
15. Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20: 541-546.
16. Wang Q, Chen Y, Xie F, et al: Development of a sandwich ELISA for evaluating soluble OX40L (CD252) in human sera of different ages or with Graves' disease. Cytokine 2006; 36: 23-28. (Pubitemid 46049016)
17. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999; 353: 983-984. (Pubitemid 29132615)
18. + T cells in an experimental model of colitis. Eur J Immunol 1997; 27: 17-25.
19. Corsini A, Maggi FM, Catapano AL: Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.
20. Martin G, Duez H, Blanquart C, et al: Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-1432. (Pubitemid 32522036)
21. McTaggart F, Jones P: Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008; 22: 321-338.
22. Ferro D, Parrotto S, Basili S, et al: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 427-431. (Pubitemid 30624003)
23. Rezaie-Majd A, Maca T, Bucek RA, et al: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-1199. (Pubitemid 34764873)
24. Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
25. Mulhaupt F, Matter CM, Kwak BR, et al: Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 755-766. (Pubitemid 38368692)
26. Türk U, Alioǧlu E, Tengiz I, et al: Statin use is associated with decreased CD-40 ligand expression on T lymphocytes of coronary atheroma plaque in patients with stable coronary artery disease. Anadolu Kardiyol Derg 2008; 8: 99-103. (Pubitemid 351586233)
27. Malyszko J, Malyszko JS, Hryszko T, et al: Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients. Blood Coagul Fibrinolysis 2004; 15: 463-467. (Pubitemid 39180230)
28. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839. (Pubitemid 36542523)
29. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.